Last reviewed · How we verify
CRMD-001-Deferiprone
Iron chelator
Iron chelator Used for Beta-thalassemia major, Sickle cell disease.
At a glance
| Generic name | CRMD-001-Deferiprone |
|---|---|
| Sponsor | CorMedix |
| Drug class | Iron chelator |
| Target | Iron |
| Modality | Small molecule |
| Therapeutic area | Rare Disease |
| Phase | Phase 2 |
Mechanism of action
Deferiprone is a small molecule that chelates iron, reducing its accumulation in tissues and mitigating oxidative stress.
Approved indications
- Beta-thalassemia major
- Sickle cell disease
Common side effects
- Gastrointestinal disturbances
- Hepatotoxicity
- Neutropenia
Key clinical trials
- Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent (PHASE3)
- Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CRMD-001-Deferiprone CI brief — competitive landscape report
- CRMD-001-Deferiprone updates RSS · CI watch RSS
- CorMedix portfolio CI